A pharmaceutical firm with a strong focus on research and development, NATCO Pharma Ltd creates, produces, and markets sophisticated pharmaceuticals for specialised therapeutic markets.
NATCO has created a foothold in all three business sectors, namely contract manufacturing, active pharmaceutical ingredients, and completed dosage formulations.
Financial Results:
The company reported a net profit of ₹62.3 crore, down 22.5% as against ₹80.4 crore year-on-year. Revenue came in at ₹492.5 crore, down 12.1% as compared to ₹560.5 crore YoY.
Management Commentary:
“So I think Q4 and Q1 will — is our expectation and most of the profit share will be booked. We’ll — we already shipped the quantify for our Q1. So I think — so we’ll have a very good Q1 and Q4, and we’ll have a very good year. So our expectation is that, this year, I think we should — overall as a company, I think we should do about INR2,700 crores to INR2,800 crores in top line, and this year PAT also should be, I think, closer to INR700 crores this year. I think that’s our expectation. Probably our highest revenue and highest PAT in the history of the company.”
– Rajeev Nannapaneni, Chief Executive Officer